

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/322,289
				Filing Date	May 28, 1999
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
Examiner Name	Kolker, Daniel E.				
Attorney Docket Number	15270J-004740US				
Sheet	1	of	3		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
/D.K.	892	6,923,964	08-02-2005	Schenk	
↓	884	2005/0152878 A1	07-14-2005	Solomon et al.	
	883	6,582,945	06-24-2003	Raso	
	885	5,798,102	08-25-1998	McMichael et al.	
U.S. PATENT APPLICATIONS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.K./	899	11/358,951	02-22-2006	Solomon et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature	/Daniel Kolker/	Date Considered	02/04/2008
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	09/322,289	
			Filing Date	May 28, 1999	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kolker, Daniel E.	
Sheet	2	of	3	Attorney Docket Number	15270J-004740US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
/D.K./	898	ASKELOF et al., "Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of <i>Bordetella pertussis</i> toxin subunit S1," <u>PNAS</u> , 87:1347-1351 (1990).	<input type="checkbox"/>	
	891	CASADESUS et al., "The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease," <u>Drugs R D</u> , 7(3):187-193 (2006).	<input type="checkbox"/>	
	901	CASEY, S.O., "Posterior Reversible Encephalopathy Syndrome: Utility of Fluid-attenuated Inversion Recovery MR Imaging in the Detection of Cortical and Subcortical Lesions," <u>Amer J Neuroradiol</u> , 21:1199-1206 (2000).	<input type="checkbox"/>	
	893	DE LA CRUZ et al, "Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <u>J Biol Chem</u> , 263(9):4318-4322 (1988).	<input type="checkbox"/>	
	902	GILMAN, S. et al., "Clinical Effects of Abeta Immunization (AN1792) in Patients with AD in an Interrupted Trial," <u>Neurology</u> , 64:1553-1562 (2005).	<input type="checkbox"/>	
	896	GROSS et al., "Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius," <u>Am J Physiol Regul Integr Comp Physiol</u> , 259:R1131-R1138 (1990).	<input type="checkbox"/>	
	887	IDUSOGIE et al., "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164:4178-4184 (2000).	<input type="checkbox"/>	
	895	KHATOON et al., "Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer's disease and control brains," <u>FEBS Letters</u> , 351:80-84 (1994).	<input type="checkbox"/>	
↓	888	KUBY, J., eds., pages 108-109, 131-132 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	<input type="checkbox"/>	

Examiner Signature	/Daniel Kolker/	Date Considered	02/04/2008
-----------------------	-----------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

(Use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number

09/322,289

Filing Date

May 28, 1999

First Named Inventor

Schenk, Dale B.

Art Unit

1649

Examiner Name _____

Kolker, Daniel E.

Attorney Docket Number

15270J-004740US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/D.K./	889	LIU et al., "Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis," <u>Proc. Natl. Acad. Sci.</u> , 95:13266-13271 (1998).	<input type="checkbox"/>
	886	MORGAN et al., "The N-terminal end of the C _H 2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc γ RII and Fc γ RII binding," <u>Immunology</u> , 86:319-324 (1995).	<input type="checkbox"/>
	903	PCT Search Report of 10/01/2007 and Written Opinion of 10/01/2007 for application PCT/US07/09499.	<input type="checkbox"/>
	890	PEREZ et al., "The β -Amyloid Precursor Protein of Alzheimer's Disease Enhances Neuron Viability and Modulates Neuronal Polarity," <u>J. Neurosci.</u> , 17(24):9407-9414 (1997).	<input type="checkbox"/>
	897	WHITCOMB et al., "Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain," <u>Am J Physiol Gastrointest Liver Physiol</u> , 259:G687-G691 (1990).	<input type="checkbox"/>
	894	WU et al., "Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of <i>Salmonella</i> ," <u>PNAS</u> , 86:4726-4730 (1989).	<input type="checkbox"/>
	900	Wyeth, Annual Review 2005: Creating Value...Advancing Health (February 27, 2006).	<input type="checkbox"/>

Examiner Signature	/Daniel Kolker/	Date Considered	02/04/2008
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.